🧠 国际心理咨询行业简报

Rejoyn (Otsuka & Click Therapeutics) — the first FDA-authorized prescription digital therapeutic for major depressive disorder — launched in the US in May 2026. The 6-week smartphone-based cognitive-emotional training program showed an average 8.78-point MADRS reduction vs. 6.66 for controls. Introductory pricing of $50 for patients makes it one of the most accessible DTx products. Lumos Labs' Prismira ADHD DTx also received FDA 510(k) clearance.

HHS formally launched an interagency working group on May 4 across seven agencies to evaluate psychiatric prescribing patterns. CMS released guidance on billing codes for deprescribing/discontinuation services. SAMHSA will host webinars (June–July) on adverse effects and non-medication alternatives. The APA expressed concerns about framing the mental health crisis as primarily an "overprescribing" problem, while AFSP warned abrupt discontinuation can increase suicide risk.

Ireland enacted a landmark 268-section Mental Health Act on May 7, featuring: first regulation of community CAMHS by the Mental Health Commission, consent rights for 16-17 year-olds equal to adults, prohibition of ECT for under-18s, and regulation of pharmacological restraint. Described as a "new era" for Irish mental healthcare.

Germany's statutory health insurance funds are planning a blanket 10% fee reduction for all psychotherapeutic services, triggering strong opposition from the German Psychotherapists Association. If implemented, it could threaten private practice viability and further extend already 5-month-long waiting lists.

Three milestones in rapid succession: Flow Neuroscience received FDA clearance for an at-home wearable depression device (58% remission at 10 weeks); Neurolief's ProlivRx became the first prescription at-home multi-channel electrical stimulation therapy for MDD (32% remission at 16 weeks); Motif Neurotech's DOT wireless implant received FDA IDE approval for first-in-human trials at Baylor, MGH, and Emory.

A major BPS study (1,175 adults, 1,933 sessions) published in the British Journal of Clinical Psychology found video therapy produced therapeutic-relationship outcomes comparable to in-person therapy, while phone sessions showed significantly weaker connection, goal agreement, and positive feelings toward therapists — especially in longer-term, intensive treatment.

TimelyCare, serving nearly 500 US college campuses, won the top telehealth award. Using validated tools (PHQ-9, GAD-7) in a measurement-based model, 76% of students achieve reliable improvement or remission after 3+ counseling visits.

ACA 2026 consensus: the therapeutic alliance remains irreplaceable, but 53% of clinicians haven't adopted AI. Paradoxically, clinicians with highest burnout are 17 percentage points more likely to adopt AI tools. Many counselors unknowingly use non-HIPAA-compliant AI for clinical work — industry standards are urgently needed.

The global online psychology counseling market reached $5.97B in 2026 (22.4% CAGR), projected to hit $13.2B by 2030. Consolidation accelerates: Teladoc acquired UpLift, Spring Health acquired Alma, NOCD acquired Rebound Health. Independent practitioners delivered 113.6M mental health sessions, continuing to dominate outpatient care delivery.